Caseware UK (AP4) 2024.0.164 2024.0.164 2025-10-31 2025-10-31 2024-11-01 false 2 2 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12274031 2024-11-01 2025-10-31 12274031 2023-11-01 2024-10-31 12274031 2025-10-31 12274031 2024-10-31 12274031 2023-11-01 12274031 c:Director1 2024-11-01 2025-10-31 12274031 d:OfficeEquipment 2024-11-01 2025-10-31 12274031 d:OtherPropertyPlantEquipment 2024-11-01 2025-10-31 12274031 d:OtherPropertyPlantEquipment 2025-10-31 12274031 d:OtherPropertyPlantEquipment 2024-10-31 12274031 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2024-11-01 2025-10-31 12274031 d:CurrentFinancialInstruments 2025-10-31 12274031 d:CurrentFinancialInstruments 2024-10-31 12274031 d:CurrentFinancialInstruments d:WithinOneYear 2025-10-31 12274031 d:CurrentFinancialInstruments d:WithinOneYear 2024-10-31 12274031 d:ShareCapital 2025-10-31 12274031 d:ShareCapital 2024-10-31 12274031 d:RetainedEarningsAccumulatedLosses 2025-10-31 12274031 d:RetainedEarningsAccumulatedLosses 2024-10-31 12274031 d:AcceleratedTaxDepreciationDeferredTax 2025-10-31 12274031 d:AcceleratedTaxDepreciationDeferredTax 2024-10-31 12274031 c:OrdinaryShareClass1 2024-11-01 2025-10-31 12274031 c:OrdinaryShareClass1 2025-10-31 12274031 c:OrdinaryShareClass1 2024-10-31 12274031 c:FRS102 2024-11-01 2025-10-31 12274031 c:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 12274031 c:FullAccounts 2024-11-01 2025-10-31 12274031 c:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 12274031 2 2024-11-01 2025-10-31 12274031 e:PoundSterling 2024-11-01 2025-10-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 12274031 OKTEM BIOPHARMA CONSULTING LTD UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 OCTOBER 2025
OKTEM BIOPHARMA CONSULTING LTD REGISTERED NUMBER: 12274031 BALANCE SHEET AS AT 31 OCTOBER 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 4 |  | 1,348 |  | 260
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 5 | 3,752 |  | 9,027 |
Cash at bank |  | 42,779 |  | 57,289 |
Current liabilities |  | 46,531 |  | 66,316 |
Creditors: amounts falling due within one year | 6 | (14,127) |  | (16,627) |
Net current assets |  |  | 32,404 |  | 49,689
Total assets less current liabilities |  |  | 33,752 |  | 49,949
Provisions for liabilities |  |  |  |  |
Deferred tax | 7 |  | (337) |  | (65)
Net assets |  |  | 33,415 |  | 49,884
Capital and reserves |  |  |  |  |
Called up share capital | 8 |  | 2 |  | 2
Profit and loss account |  |  | 33,413 |  | 49,882
|  |  | 33,415 |  | 49,884
Page 1
OKTEM BIOPHARMA CONSULTING LTD REGISTERED NUMBER: 12274031 BALANCE SHEET (CONTINUED) AS AT 31 OCTOBER 2025 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
Dr K Haque
Director
Date: 9 April 2026
The notes on pages 3 to 8 form part of these financial statements. Page 2
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025
1. | General information
Oktem Biopharma Consulting Ltd is a private Company limited by shares, incorporated in England and Wales within the United Kingdom. The address of the registered office is Tennyson House, Cambridge Business Park, Cambridge, CB4 0WZ. This Company is not part of a group. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the requirements and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The following principal accounting policies have been applied:
| 2.2 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.3 | Interest income
Interest income is recognised in profit or loss using the effective interest method.
| 2.4 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds. Page 3
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025 2.Accounting policies (continued)
| 2.5 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
| 2.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | Office equipment | - | 33% | straight line
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss. Page 4
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025 2.Accounting policies (continued)
| 2.7 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.8 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.9 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.10 | Provisions for liabilities
Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made. Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties. Deferred tax liabilities are also presented within provisions but are measured in accordance with the accounting policy on taxation. Increases in provisions are generally charged as an expense to profit or loss. Page 5
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025 2.Accounting policies (continued)
| 2.11 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments. Basic financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.
| 2.12 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.
3. | Employees
| The average monthly number of employees, including directors, during the year was 2 (2024 - 2).
Page 6
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025
4. | Tangible fixed assets
|  | Other fixed assets
|  | £
| Cost |
| At 1 November 2024 | 3,396
| Additions | 1,880
| Disposals | (292)
| At 31 October 2025 | 4,984
| Depreciation |
| At 1 November 2024 | 3,136
| Charge for the year on owned assets | 792
| Disposals | (292)
| At 31 October 2025 | 3,636
| Net book value |
| At 31 October 2025 | 1,348
| At 31 October 2024 | 260
5. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade debtors | 3,430 | 8,687
| Prepayments | 322 | 340
|  | 3,752 | 9,027
Page 7
OKTEM BIOPHARMA CONSULTING LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2025
6. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Corporation tax | 2,929 | 5,982
| Other taxation and social security | 238 | 1,133
| Other creditors | 624 | -
| Accruals | 10,336 | 9,512
|  | 14,127 | 16,627
7. | Deferred taxation
|  | 2025 | 2024
|  | £ | £
| At beginning of year | (65) | (130)
| Charged to profit or loss | (272) | 65
| At end of year | (337) | (65)
| The provision for deferred taxation is made up as follows:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Accelerated capital allowances | (337) | (65)
8. | Share capital
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 2 (2024 - 2) Ordinary shares of £1.00 each | 2 | 2
9. | Related party transactions
| During the year the Company operated a loan with a director of the Company. The amount payable to the director of the Company at the year end was £624 (2024 - £Nil). This loan is interest free and repayable on demand.
Page 8